B.Riley FBR Keeps a Buy Rating on Miragen Therapeutics (MGEN) and $18.5000 Target; Last Week Group 1 Automotive, Inc. (GPI) Coverage

May 17, 2018 - By Nellie Frank

Group 1 Automotive, Inc. (NYSE:GPI) Logo

Equities researchers at B.Riley FBR have $18.5000 TP on Miragen Therapeutics Inc (MGEN). B.Riley FBR’s TP suggests a potential upside of 148.32% from the company’s last stock close price. The rating was disclosed in a research note on Thursday morning.

Among 14 analysts covering Group 1 Automotive (NYSE:GPI), 2 have Buy rating, 1 Sell and 11 Hold. Therefore 14% are positive. Group 1 Automotive had 26 analyst reports since September 17, 2015 according to SRatingsIntel. The stock of Group 1 Automotive, Inc. (NYSE:GPI) earned “Underweight” rating by Morgan Stanley on Wednesday, March 14. The rating was downgraded by Goldman Sachs on Tuesday, November 22 to “Sell”. The firm earned “Hold” rating on Monday, November 13 by KeyBanc Capital Markets. The stock of Group 1 Automotive, Inc. (NYSE:GPI) earned “Neutral” rating by Susquehanna on Thursday, February 2. The rating was downgraded by CL King on Tuesday, January 10 to “Neutral”. Wells Fargo maintained the shares of GPI in report on Monday, October 30 with “Market Perform” rating. On Thursday, August 31 the stock rating was maintained by KeyBanc Capital Markets with “Hold”. On Tuesday, August 9 the stock rating was initiated by Seaport Global with “Neutral”. The firm has “Hold” rating by Stephens given on Friday, February 9. The firm has “Buy” rating given on Thursday, September 17 by Sidoti. See Group 1 Automotive, Inc. (NYSE:GPI) latest ratings:

16/04/2018 Broker: Guggenheim Rating: Hold Initiate
16/04/2018 Broker: Stephens Rating: Hold New Target: $88.0000 Maintain
20/03/2018 Broker: Stephens Rating: Hold New Target: $86.0 Maintain
20/03/2018 Broker: Buckingham Research Old Rating: Buy New Rating: Neutral Downgrade
14/03/2018 Broker: Morgan Stanley Old Rating: Underweight New Rating: Underweight Old Target: $53 New Target: $62 Maintain
09/02/2018 Broker: Stephens Rating: Hold New Target: $98.0 Maintain
09/02/2018 Broker: Bank of America Old Rating: Buy New Rating: Buy Old Target: $103 New Target: $105 Maintain
05/01/2018 Broker: Buckingham Research Rating: Buy Upgrade

Among 9 analysts covering Miragen Therapeutics (MGEN), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Miragen Therapeutics has $19.0 highest and $1300 lowest target. $16.29’s average target is 118.66% above currents $7.45 stock price. Miragen Therapeutics had 22 analyst reports since February 21, 2017 according to SRatingsIntel. The rating was initiated by Oppenheimer on Tuesday, March 27 with “Buy”. The firm has “Buy” rating given on Thursday, May 10 by FBR Capital. The rating was maintained by Wedbush with “Buy” on Friday, December 1. Wedbush maintained Miragen Therapeutics, Inc. (NASDAQ:MGEN) on Monday, October 16 with “Buy” rating. The rating was initiated by Oppenheimer with “Buy” on Thursday, January 11. Wedbush initiated it with “Outperform” rating and $19.0 target in Tuesday, February 21 report. The rating was maintained by FBR Capital with “Buy” on Tuesday, March 27. The company was maintained on Monday, August 14 by Chardan Capital Markets. The firm has “Buy” rating given on Tuesday, March 20 by Wedbush. The rating was maintained by Wedbush with “Buy” on Monday, April 30.

Analysts await Miragen Therapeutics, Inc. (NASDAQ:MGEN) to report earnings on August, 10. They expect $-0.26 earnings per share, up 23.53% or $0.08 from last year’s $-0.34 per share. After $-0.18 actual earnings per share reported by Miragen Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 44.44% negative EPS growth.

Miragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. The company has market cap of $225.08 million. The Company’s two lead product candidates, MRG-106 and MRG-201 are in Phase 1 clinical trials. It currently has negative earnings. The company??s clinical product candidate for the treatment of certain cancers, MRG-106, is an inhibitor of microRNA-155, which is found at abnormally high levels in various blood cancers.

More notable recent Miragen Therapeutics, Inc. (NASDAQ:MGEN) news were published by: Streetinsider.com which released: “miRagen Therapeutics (MGEN) to Present New Interim Data From Phase 1 Clinical Trial of Cobomarsen at ASCO” on May 16, 2018, also Seekingalpha.com with their article: “miRagen Therapeutics’ (MGEN) CEO William Marshall on Q1 2018 Results – Earnings Call Transcript” published on May 10, 2018, Nasdaq.com published: “miRagen Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update” on May 09, 2018. More interesting news about Miragen Therapeutics, Inc. (NASDAQ:MGEN) were released by: Streetinsider.com and their article: “miRagen Therapeutics (MGEN) to Highlight New Interim Data From Phase 1 Clinical Trial of Cobomarsen in Mycosis …” published on May 09, 2018 as well as Nasdaq.com‘s news article titled: “miRagen Therapeutics to Report First Quarter 2018 Financial Results and Host Conference Call on May 9, 2018” with publication date: May 02, 2018.

The stock decreased 0.73% or $0.06 during the last trading session, reaching $7.45. About 154,537 shares traded. Miragen Therapeutics, Inc. (MGEN) has declined 43.43% since May 17, 2017 and is downtrending. It has underperformed by 54.98% the S&P500.

More important recent Group 1 Automotive, Inc. (NYSE:GPI) news were published by: Streetinsider.com which released: “Group 1 Automotive (GPI) Boosts Buyback Plan by $100 Million” on May 16, 2018, also Streetinsider.com published article titled: “Elliott’s 13F Shows New Stake in Commault (CVLT), Dish (DISH), Micro Focus (MFGP) (more…)”, Seekingalpha.com published: “Group 1 Automotive (GPI) Q1 2018 Results – Earnings Call Transcript” on April 26, 2018. More interesting news about Group 1 Automotive, Inc. (NYSE:GPI) was released by: Seekingalpha.com and their article: “Congress slaps down CFPB’s auto lending guidance” with publication date: May 09, 2018.

The stock increased 2.11% or $1.5 during the last trading session, reaching $72.64. About 116,365 shares traded. Group 1 Automotive, Inc. (NYSE:GPI) has declined 13.27% since May 17, 2017 and is downtrending. It has underperformed by 24.82% the S&P500.

Investors sentiment increased to 1.21 in 2017 Q4. Its up 0.22, from 0.99 in 2017Q3. It is positive, as 22 investors sold Group 1 Automotive, Inc. shares while 56 reduced holdings. 44 funds opened positions while 50 raised stakes. 20.23 million shares or 0.17% less from 20.26 million shares in 2017Q3 were reported. Texas Permanent School Fund accumulated 13,254 shares. The Hong Kong-based Parametrica Management has invested 0.24% in Group 1 Automotive, Inc. (NYSE:GPI). Moreover, Credit Suisse Ag has 0% invested in Group 1 Automotive, Inc. (NYSE:GPI) for 18,689 shares. Old Mutual Customised Solutions (Proprietary) Ltd has 0.01% invested in Group 1 Automotive, Inc. (NYSE:GPI). Hodges Capital Mngmt holds 1.1% or 211,867 shares. Teachers Retirement Of The State Of Kentucky has 0.01% invested in Group 1 Automotive, Inc. (NYSE:GPI). Tiaa Cref Investment Ltd Liability Co invested 0.01% of its portfolio in Group 1 Automotive, Inc. (NYSE:GPI). 131 are held by Sei Invs. Hsbc Holdg Public Limited Company reported 7,645 shares. Eqis Cap invested 0.01% in Group 1 Automotive, Inc. (NYSE:GPI). The New York-based Cornerstone Cap Hldg Lc has invested 0% in Group 1 Automotive, Inc. (NYSE:GPI). Metropolitan Life Ny reported 0.01% stake. Moreover, Guggenheim Ltd has 0% invested in Group 1 Automotive, Inc. (NYSE:GPI). Goldman Sachs Gru Inc holds 0% of its portfolio in Group 1 Automotive, Inc. (NYSE:GPI) for 168,810 shares. Ls Invest Advsrs Limited Liability Corp reported 578 shares.

Group 1 Automotive, Inc. (NYSE:GPI) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


>